Novo CEO Doustdar 'Very Optimistic' About CagriSema

Novo Nordisk A/S Chief Executive Officer Mike Doustdar discusses the possible launch of a new obesity drug called CagriSema. "We are hopeful that we will be able to get the timely approval from the…